【摘要】 目的评估苦参素与α-2b干扰素联合应用在慢性乙肝患儿中的疗效。方法实验分两组:INF组:给30名乙肝患儿皮下注射α-2b干扰素300万单位/次,每周3次,共6个月;INF+苦参素组:给30名患儿苦参素注射液400mg/天,肌肉注射,连用3个月,外加INF治疗6个月。结果治疗结束时,INF组和联合治疗组的HBeAg的转阴率分别为23.0%和27.0%(p>0.05);HBVDNA的转阴率分别为30.0%和23.0%;(p>0.05);ALT的复常率为53.0%和80.0%;TSB的复常率分别为57.0%和83.0%(p<0.05)。结论苦参素与α-2b干扰素联合治疗可以促进慢性乙肝患儿肝功能的恢复。更多还原

【Abstract】 Objective To evaluate the efficacy of α-2b interferon combined with marini on children with chronic hepatitis B. Methods 60 children with CHB were randomly divided into two groups. Group INF was only given α-2b INF (30 million international units /d) three times a week for six months. Group INF+ marini group was given α-2bINF for six months and marini(400mg/d,i.m)for three months. Results At the end of treatment, the ALT and TSB normalization rate were53.0%,57.0% in group INF, respectively. 80.0%,83.0% in group INF+ Marini.The different were significant.(p<0.05).There were no significant difference in the HBV DNA seroconversion rate and HBeAg negative rate between two groups (p>0.05). Conclusions INF+Marini therapy for chronic hepatitis B is more effective than INF monotherapy in improving liver function.更多还原